Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice
about
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2pNaKtide Attenuates Steatohepatitis and Atherosclerosis by Blocking Na/K-ATPase/ROS Amplification in C57Bl6 and ApoE Knockout Mice Fed a Western Diet.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM.Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sitesPPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptorsActivation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseasePemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Nuclear receptors and nonalcoholic fatty liver disease.Preclinical models of atherosclerosis. The future of Hybrid PET/MR technology for the early detection of vulnerable plaque.High-glucose-increased expression and activation of NADPH oxidase in human vascular smooth muscle cells is mediated by 4-hydroxynonenal-activated PPARα and PPARβ/δ.Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferasePPARalpha regulates the production of serum Vanin-1 by liver.5,7-Dimethoxyflavone, an activator of PPARα/γ, inhibits UVB-induced MMP expression in human skin fibroblast cells.The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
P2860
Q28488385-0A7C55AE-36C0-455D-BBA4-1D87AA39DF90Q33671222-2DE39BE0-4EAE-4524-BBA0-E10B9187576AQ34041838-1EBA98B7-60AF-4FAD-A4AA-DF2397459746Q34480492-AFA8FD37-3FEB-4EBE-9D80-E4205473A4AEQ34776084-BAFEA6C6-F759-4D74-A4E2-FABA6F343AD7Q35415945-7BA127EF-2E6E-4641-9D72-E6DEB69A5814Q35561941-3715BAD7-6FE4-48F8-ACF0-620CC2D6FF21Q35739204-E8D1B045-F4DA-434A-8598-9EDCCF239F59Q36253614-3491C612-166C-4F2B-BE2B-6C8D1F21969DQ36733873-43DF51F4-A462-428D-9429-1FB959DAE2E7Q36867522-097345C1-04EF-4294-8D07-A18B27D11046Q37196514-BB5F31E1-1EB3-4FF7-A319-EEEE54EF4A6AQ37640263-359DAEA8-6C25-4E37-B575-8811B4FD2003Q37699483-9EC24175-11E1-47F3-972C-E4340B3C889DQ38752520-27AD77C3-234F-4272-987C-8444E3C5E36EQ38768048-3A26ED14-DFEB-4AC3-9266-7F6673DE12E4Q38801539-E8309814-AAF4-4927-BB3D-9C4020688A4EQ38905577-9FD95FED-176A-4CAE-AF25-B41B8BEC018BQ41457655-91569762-C2CB-48AD-AA83-04519255B5D1Q41776542-89BA9405-D9F8-46EE-954C-00B98AAE25DCQ45775414-C7B9488C-01B4-4675-8663-BCD2732B41ABQ54321268-584EC0C7-240F-418D-84EB-7E667179D816Q58699539-72BC1354-4178-4F5E-B36F-7D2C309CBF8C
P2860
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@ast
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@en
type
label
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@ast
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@en
prefLabel
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@ast
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@en
P2093
P2860
P50
P1476
Peroxisome proliferator-activa ...... polipoprotein E2 knock-in mice
@en
P2093
Emmanuelle Vallez
Jonathan Vanhoutte
Marten Hofker
Morgane Baron
Sandrine Caron
P2860
P304
P356
10.1161/ATVBAHA.110.220525
P407
P577
2011-04-07T00:00:00Z